Prosight Management, LP X4 Pharmaceuticals, Inc Transaction History
Prosight Management, LP
- $348 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding XFOR
# of Institutions
106Shares Held
103MCall Options Held
206KPut Options Held
291K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$9.81 Million3.55% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$8.69 Million1.46% of portfolio
-
Black Rock Inc. New York, NY8.74MShares$5.07 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.83MShares$4.54 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.14 Million0.22% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $39.8M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...